Company intelligence / Profile preview

Parataxis Capital Management

New York, New York, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Parataxis Capital is a digital asset-focused multi-strategy hedge fund, not a drug developer. Its recent acquisition of Bridge Biotherapeutics (now Parataxis Korea) pivots the acquired company to a hybrid model—maintaining some biotech R&D while establishing a Bitcoin treasury company in South Korea.

Industry: Investors

Beyond the preview

Go deeper on Parataxis Capital Management.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Parataxis Capital Management.

Explore the full profile